Cargando…

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

BACKGROUND: Adalimumab (ADA) (Humira(®), AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis. OBJECTIVES: To evaluate the long‐term efficacy and safety of ADA in children with severe plaque psoriasis. METHODS: Results are present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thaçi, D., Papp, K., Marcoux, D., Weibel, L., Pinter, A., Ghislain, P.‐D., Landells, I., Hoeger, P.H., Unnebrink, K., Seyger, M.M.B., Williams, D.A., Rubant, S., Philipp, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916374/ https://www.ncbi.nlm.nih.gov/pubmed/31017657 http://dx.doi.org/10.1111/bjd.18029

Ejemplares similares

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial
por: Thaçi, D., et al.
Publicado: (2021)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH
por: Poulin, Y, et al.
Publicado: (2014)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2022)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Adalimumab-induced systemic lupus erythematosus: A case report and review of the literature
por: Landells, Fiona M, et al.
Publicado: (2023)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab
por: Chu, Yuqi, et al.
Publicado: (2022)

AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
por: Hercogová, J., et al.
Publicado: (2019)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients
por: Bruins, F.M., et al.
Publicado: (2020)

Real-world Methotrexate Use in a Prospective Cohort of Paediatric Patients with Plaque Psoriasis: Effectiveness, Adverse Events and Folic Acid Regimen
por: BRUINS, Finola M., et al.
Publicado: (2022)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
por: Papp, K.A., et al.
Publicado: (2021)

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
por: Moore, Angela Y, et al.
Publicado: (2010)

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment
por: Reich, K., et al.
Publicado: (2019)

Image‐based automated Psoriasis Area Severity Index scoring by Convolutional Neural Networks
por: Schaap, M.J., et al.
Publicado: (2021)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

The content validity of the PSS in patients with plaque psoriasis
por: Rentz, A. M., et al.
Publicado: (2017)

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis
por: Burgos-Vargas, R, et al.
Publicado: (2013)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis
por: Zdanowska, Natalia, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
por: Armstrong, April W., et al.
Publicado: (2023)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study
por: Gottlieb, A.B., et al.
Publicado: (2021)

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
por: Cai, L., et al.
Publicado: (2016)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
por: van Acht, Maartje R, et al.
Publicado: (2022)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis‐Related Arthritis
por: Burgos‐Vargas, Rubén, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bf2hh96ar6rd9rnppedkptvrhr